CONTACT US
Home > Inhibitors/Agonists> > Omecamtiv mecarbil
Omecamtiv mecarbil

Omecamtiv mecarbil

  • CAT Number: I005262
  • CAS Number: 873697-71-3
  • Molecular Formula: C20H24FN5O3
  • Molecular Weight: 401.4
  • Purity: ≥95%
Inquiry Now

Omecamtiv mecarbil (CAT: I005262) is a selective cardiac myosin activator that enhances the contractility of the heart muscle. It works by binding to the cardiac myosin protein and increasing its interaction with actin, resulting in increased force generation and improved cardiac function. Omecamtiv mecarbil has been investigated as a potential treatment for heart failure, aiming to improve cardiac performance and alleviate symptoms in patients with reduced ejection fraction. Clinical studies have shown promising results, demonstrating its ability to increase cardiac output and improve exercise capacity in heart failure patients. It represents a novel therapeutic approach for the management of heart failure and is currently being evaluated for its efficacy and safety in ongoing clinical trials.

Catalog Number I005262
CAS Number 873697-71-3
Molecular Formula

C20H24FN5O3

Purity 95%
Target ATPase
Solubility DMSO ≥78mg/mL Water <1.2mg/mL Ethanol ≥12mg/mL
Storage 3 years -20C powder
Overview of Clinical Research

<span style=”font-size:12px;”><span style=”font-family:arial,helvetica,sans-serif;”>Omecamtiv mecarbil is a cardiac myosin stimulant.&nbsp;</span></span>

IC50 0.6 uM (EC50)
IUPAC Name methyl 4-[[2-fluoro-3-[(6-methylpyridin-3-yl)carbamoylamino]phenyl]methyl]piperazine-1-carboxylate
InChI InChI=1S/C20H24FN5O3/c1-14-6-7-16(12-22-14)23-19(27)24-17-5-3-4-15(18(17)21)13-25-8-10-26(11-9-25)20(28)29-2/h3-7,12H,8-11,13H2,1-2H3,(H2,23,24,27)
InChIKey RFUBTTPMWSKEIW-UHFFFAOYSA-N
SMILES COC(N1CCN(CC2=CC=CC(NC(NC3=CC=C(C)N=C3)=O)=C2F)CC1)=O
Reference

<br />
1:Omecamtiv mecarbil activates ryanodine receptors from canine cardiac but not skeletal muscle. N&aacute;n&aacute;si P Jr, Gaburjakova M, Gaburjakova J, Alm&aacute;ssy J.Eur J Pharmacol. 2017 May 13. pii: S0014-2999(17)30347-3. doi: 10.1016/j.ejphar.2017.05.027. [Epub ahead of print] PMID: 28506910<br />
2:Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction. Psotka MA, Teerlink JR.Handb Exp Pharmacol. 2017 Mar 18. doi: 10.1007/164_2017_13. [Epub ahead of print] PMID: 28315072<br />
3:Omecamtiv Mecarbil Enhances the Duty Ratio of Human &beta;-Cardiac Myosin Resulting in Increased Calcium Sensitivity and Slowed Force Development in Cardiac Muscle. Swenson AM, Tang W, Blair CA, Fetrow CM, Unrath WC, Previs MJ, Campbell KS, Yengo CM.J Biol Chem. 2017 Mar 3;292(9):3768-3778. doi: 10.1074/jbc.M116.748780. Epub 2017 Jan 12. PMID: 28082673<br />
4:Heart failure: Phase II trial results of omecamtiv mecarbil. Lim GB.Nat Rev Cardiol. 2017 Feb;14(2):66. doi: 10.1038/nrcardio.2016.205. Epub 2016 Dec 15. No abstract available. PMID: 27974808<br />
5:Dose-dependent electrophysiological effects of the myosin activator omecamtiv mecarbil in canine ventricular cardiomyocytes. Szentandrassy N, Horvath B, Vaczi K, Kistamas K, Masuda L, Magyar J, Banyasz T, Papp Z, Nanasi PP.J Physiol Pharmacol. 2016 Aug;67(4):483-489. PMID: 27779469 Free Article<br />
6:The myosin activator omecamtiv mecarbil: a promising new inotropic agent. N&aacute;n&aacute;si P Jr, V&aacute;czi K, Papp Z.Can J Physiol Pharmacol. 2016 Oct;94(10):1033-1039. Epub 2016 Feb 12. PMID: 27322915<br />
7:Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. Teerlink JR, Felker GM, McMurray JJ, Ponikowski P, Metra M, Filippatos GS, Ezekowitz JA, Dickstein K, Cleland JG, Kim JB, Lei L, Knusel B, Wolff AA, Malik FI, Wasserman SM; ATOMIC-AHF Investigators..J Am Coll Cardiol. 2016 Mar 29;67(12):1444-55. doi: 10.1016/j.jacc.2016.01.031. PMID: 27012405 Free Article<br />
8:Response to Letter Regarding Article, /Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity/. Bakkehaug JP, Kildal AB, Engstad ET, Boardman N, N&aelig;sheim T, R&oslash;nning L, Aasum E, Larsen TS, Myrmel T, How OJ.Circ Heart Fail. 2015 Nov;8(6):1142. doi: 10.1161/CIRCHEARTFAILURE.115.002548. No abstract available. PMID: 26738203 Free Article<br />
9:Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects. Palaparthy R, Banfield C, Alvarez P, Yan L, Smith B, Johnson J, Monsalvo ML, Malik F.Int J Clin Pharmacol Ther. 2016 Mar;54(3):217-27. doi: 10.5414/CP202458. PMID: 26709596 Free PMC Article<br />
10:Manufacturing of [(14)C]-Labeled Drug Substance and Drug Product Utilized in Clinical Research: A Case Study of Omecamtiv Mecarbil. Roberts SW, Bezemer JM, Kennedy MT, Correll TL, Subramanian R, Walker SD.Curr Pharm Des. 2016;22(5):609-15. Review. PMID: 26708829

Request a Quote

Contact Us at MuseChem

We are committed to providing you with reliable, cost-effective solutions for your chemical needs, while ensuring your safety and comfort. Our team of experts is always available to answer your questions and help you navigate the complexities of the chemical industry.

Whether you're looking for a specific product or need help with a custom synthesis project, we're here to help you discover a new world of chemical possibilities. Contact us today to learn more about how we can assist you with all of your chemical needs.

Our goal is to make the process of ordering chemicals as seamless and hassle-free as possible. Let us know how we can assist you, and we'll get back to you as soon as possible. We look forward to hearing from you!